Hdl Handle:
http://hdl.handle.net/10147/303553
Title:
Meningococcal B vaccine
Authors:
Murphy, JFA
Affiliation:
Irish Medical Journal (IMJ)
Publisher:
Irish Medical Journal (IMJ)
Journal:
Irish Medical Journal (IMJ)
Issue Date:
Oct-2013
URI:
http://hdl.handle.net/10147/303553
Language:
en
Description:
Bexsero, a 4 component protein-based meningococcal B vaccine (4CMen B) manufactured by Novartis was authorised for use by the European Medicines1 in January 2013. The development of 4C Men B has taken long years of research because of the similarity between the serogroup B capsule and the human antigen neural-cell adhesion molecules. It necessitated a new approach called reverse vaccinology which involves whole-genome sequencing of bacteria and the identification of proteins that provoke an immunological response. The 4CMen B vaccine has 4 antigenic components. The clinical trials have involved 8000 children. One month after the third dose, 84-100 per cent had a satisfactory immunological response2. The new vaccine should protect against 73% of the strains that cause the disease. The recommended immunisation for infants is 3 doses commencing at 2 months with 2 further doses at least 1 month apart. For unvaccinated older children 2 doses are recommended. Since 1999 serogroup C conjugate vaccine has been available for the prevention of meningococcal C disease and has led to a dramatic reduction in the incidence of the disease.
Keywords:
MENINGITIS; IMMUNISATION

Full metadata record

DC FieldValue Language
dc.contributor.authorMurphy, JFAen_GB
dc.date.accessioned2013-10-17T16:48:16Z-
dc.date.available2013-10-17T16:48:16Z-
dc.date.issued2013-10-
dc.identifier.urihttp://hdl.handle.net/10147/303553-
dc.descriptionBexsero, a 4 component protein-based meningococcal B vaccine (4CMen B) manufactured by Novartis was authorised for use by the European Medicines1 in January 2013. The development of 4C Men B has taken long years of research because of the similarity between the serogroup B capsule and the human antigen neural-cell adhesion molecules. It necessitated a new approach called reverse vaccinology which involves whole-genome sequencing of bacteria and the identification of proteins that provoke an immunological response. The 4CMen B vaccine has 4 antigenic components. The clinical trials have involved 8000 children. One month after the third dose, 84-100 per cent had a satisfactory immunological response2. The new vaccine should protect against 73% of the strains that cause the disease. The recommended immunisation for infants is 3 doses commencing at 2 months with 2 further doses at least 1 month apart. For unvaccinated older children 2 doses are recommended. Since 1999 serogroup C conjugate vaccine has been available for the prevention of meningococcal C disease and has led to a dramatic reduction in the incidence of the disease.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journal (IMJ)en_GB
dc.subjectMENINGITISen_GB
dc.subjectIMMUNISATIONen_GB
dc.titleMeningococcal B vaccineen_GB
dc.contributor.departmentIrish Medical Journal (IMJ)en_GB
dc.identifier.journalIrish Medical Journal (IMJ)en_GB
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.